Administration of DDD (2,2-bis (parachlorophenyl)-1,1-dichloroethane) to diabetics with hyaline vascular changes and hyperpolysaccharidemia.
D000302:Adrenal Cortex / Q000187:drug effects*; D003634:DDT / Q000031:analogs & derivatives; D048909:Diabetes Complications; D003920:Diabetes Mellitus; D003632:Dichlorodiphenyldichloroethane; D005018:Ethyl Chloride / Q000031:analogs & derivatives; D005025:Ethylene Dichlorides; D005128:Eye Diseases / Q000209:etiology*; D006818:Hyalin; D007668:Kidney / Q000187:drug effects*; D004364:Pharmaceutical Preparations; D011134:Polysaccharides / Q000097:blood*
D005025:Ethylene Dichlorides; D004364:Pharmaceutical Preparations; D011134:Polysaccharides; C501196:1,1-dichloroethane; D005018:Ethyl Chloride; D003634:DDT; D003632:Dichlorodiphenyldichloroethane
ADRENAL CORTEX/effect of drugs on; DDT/related compounds; DIABETES MELLITUS/complications; EYE DISEASES/etiology and pathogenesis; KIDNEYS/effect of drugs on; POLYSACCHARIDES/in blood